Global Hypertriglyceridemia Market, By Drug Class (Statins, Fibrates, Niacin, Omega-3 fatty acids, HMG-CoA reductase inhibitors), Type (Primary Hypertriglyceridemia, Secondary Hypertriglyceridemia, Others), Treatment (Pharmacological, Non-Pharmacological, Emerging Treatments, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Hypertriglyceridemia Market Analysis and Size
The global sialorrhea market is expected to witness significant growth during the forecast period. Approvals of drugs and product launches are projected to create much growth opportunities for market players operating in the global hypertriglyceridemia market. This increasing triglyceride levels are primarily associated with predisposing cardiovascular diseases and atherosclerosis, even in the absence of high cholesterol levels. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global hypertriglyceridemia market in the forecast period 2022-2029. The expected CAGR of global hypertriglyceridemia market is tend to be around 4.59% in the mentioned forecast period. The market was valued at USD 10162.59 million in 2021, and it would grow upto USD 14552.10 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hypertriglyceridemia Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Statins, Fibrates, Niacin, Omega-3 fatty acids, HMG-CoA reductase inhibitors), Type (Primary Hypertriglyceridemia, Secondary Hypertriglyceridemia, Others), Treatment (Pharmacological, Non-Pharmacological, Emerging Treatments, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare (U.K.), Wockhardt (India)
|
|
Market Opportunities
|
|
Market Definition
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms of hypertriglyceridemia.
Global Hypertriglyceridemia Market Dynamics
Drivers
- Increased Consumption of Unhealthy Diet
Higher consumption of unhealthy food and lifestyle is projected to expand the scope of growth of the global hypertriglyceridemia market. Increased demand for hypertriglyceridemia medications for use in the point-of-care healthcare sector to provide a solution for the requirement of preventive methods, is in return is, increasing the demand for this market.
- Higher Drug Approvals
The growing number of drug approvals are anticipated to help companies build their market position. For instance, in December 2019, Amarin received FDA approval for VASCEPA (icosapent ethyl) which is indicated for reducing cardiovascular risk. The novel indication for VASCEPA is that it is an adjunct to diet to diminish triglyceride levels in aged patients with severe hypertriglyceridemia. This boosts the market growth.
Opportunities
- Growing Elderly Population
Life expectancy is increasing all over the globe, which has led to an upsurge in the aging population. This trend positively impacts the industry by increasing the disease occurrence and creating per capita demand for its remedies. A rise in elderly visits to outpatient facilities and ambulatory surgery centers (ASC) results in the sound growth of the global hypertriglyceridemia market during the forecast period. Thus, it creates more opportunities for the market growth.
- Increased R&D Activities
Major market players are investing to in development of novel drugs and launching these products in the market which in turn, is projected to significantly increase the market growth and create productive growth opportunities in the global hypertriglyceridemia market during the forecast period. For instance, in July 2019, Sun Pharma launched ‘Ezallor Sprinkle’ in the U.S. for people with difficulty swallowing. Ezallor Sprinkle capsules are indicated as an addition to the diet for the treatment of hypertriglyceridemia adult patient. It is also indicated for treating adult patients with type III hyperlipoproteinemi and other lipid-lowering treatments. These new treatment methods are creating more opportunities for the market.
Restraints/Challenges
- Lack of Medical Care
The lack of medical care in undeveloped economies may restrain the growth of hypertriglyceridemia market during the forecast period. Not much awareness leads to the unavailability of treatment and limits market growth.
- High Cost
The huge expenditure associated with these therapeutics such as fibrates, niacin, omega-3 fatty acids hamper the market growth. The huge drug development and associated processes hamper the market's growth.
This global hypertriglyceridemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hypertriglyceridemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Covid-19 Impact on Global Hypertriglyceridemia Market
The hypertriglyceridemia market growth has been impacted majorly because of COVID-19 worldwide. According to EMCrit project, COVID-19 affected patients are more susceptible to having hypertriglyceridemia, primarily because of systemic inflammation. Therefore, ideally keeping the propofol dosages can help to maintain sedation and prevent conditions such as hypertriglyceridemia. It is difficult for several researchers and major market players to perform clinical trials during this pandemic crisis. However, in the post-pandemic era, numerous market players such as Eli Lilly and Company, and Pfizer are investing in research and development of novel hypertriglyceridemia drugs.
Global Hypertriglyceridemia Market Scope
The global hypertriglyceridemia market is segmented on the basis of type, drugs, drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Primary Hypertriglyceridemia
- Secondary Hypertriglyceridemia
- Others
Drugs
- Pharmacological
- Non-Pharmacological
- Emerging Treatments
- Others
Drug class
- Statins
- Atorvastatin
- Fluvastatin
- Fibrates
- Clofibrate
- Fenofibrate
- Niacin
- Nicotinic acid
- Nicotinamide
- Omega-3 Fatty Acids
- Alpha-linolenic acid (ALA)
- HMG-CoA Reductase inhibitors
- Altoprev
- Amlodipine/atorvastatin.
- Atorvastatin
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Hypertriglyceridemia Market Regional Analysis/Insights
The global hypertriglyceridemia market is analysed and market size insights and trends are provided by type, drugs, drug class, distribution channel and end-user as referenced above.
The major countries covered in the global hypertriglyceridemia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing positive growth for global hypertriglyceridemia market throughout the forecasted period due to advanced healthcare facilities and the presence of multiple treatment options.
North America dominates the market due to increased public–private partnerships to promote R&D activities for treatment of sialorrhea in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hypertriglyceridemia Market Share Analysis
The global hypertriglyceridemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hypertriglyceridemia market.
Key players operating in the global hypertriglyceridemia market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (Japan)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Accord Healthcare (U.K.)
- Wockhardt (India)
SKU-